New insights to enhance treatment and diagnosis of blood cancer

A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKCα in causing t(4;14) translocated multiple myeloma (MM), a high-risk subtype of blood cancer, to be more aggressive and resistant to treatment.

Ketogenic diet and its effects on tumour growth and ‘wasting syndrome’

Professor Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore at the National University of Singapore, together with Assistant Professor Tobias Janowitz, Principal Investigator at the Cold Spring Harbor Laboratory in New York, and an international group of researchers from the USA and UK, have discovered that ketogenic diets delay tumour growth but accelerate cachexia, a wasting syndrome, an unintended side effect that could cause death.

Triple-drug therapy for post-transplant management of multiple myeloma

Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.

Sylvester Comprehensive Cancer Center Receives Approval to Build World-Class Myeloma Research Institute

The Myeloma Research Institute’s launch follows many important accomplishments by C. Ola Landgren, M.D., Ph.D. and his team, who are dedicated to fulfilling a promise of providing the best cancer care to myeloma patients. Florida is among the states with the highest rates of new myeloma diagnoses in the U.S., with 7.9 cases diagnosed in every 100,000 of the state’s residents.

MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting

Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.

Dr. Mohamad Cherry of Atlantic Health System Presents Studies at Top International Blood Cancer Meeting

Dr. Cherry focused on results from a Juno Therapeutics phase 2 study of liso-cel, an investigational CAR T therapy being tested against aggressive relapsed/refractory B cell non-Hodgkin lymphoma. Early results indicate a good safety profile, with few adverse events reported. Dr. Cherry also presented on the final results of a phase 1 study of targeted therapy gilteritinib in newly diagnosed acute myeloid leukemia (AML). Gilteritinib targets the most common mutation that causes AML, the FLT3 gene. Gilteritinib is sold under the brand name Xospata® by Astellas Pharma.

Sequencing Study from Roswell Park Highlights Previously Unknown Myeloma Resistance Mechanisms

— A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma. Findings from the study will be presented today at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held virtually.

Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma

Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.

Robbins Family Awards Honor Exemplary Service In Nursing at Memorial Sloan Kettering

As we celebrate National Nurses Week, Memorial Sloan Kettering Cancer Center (MSK) and The Robbins Family Foundation recognize seven distinguished nursing staff members for their exemplary service. Each member of this select group is being honored with the inaugural 2020 Robbins Family Award for Nursing Excellence.